首页> 外文期刊>Biomedicine & pharmacotherapy =: Biomedecine & pharmacotherapie >Ferulic acid ameliorates nonalcoholic fatty liver disease and modulates the gut microbiota composition in high-fat diet fed ApoE(-/-) mice
【24h】

Ferulic acid ameliorates nonalcoholic fatty liver disease and modulates the gut microbiota composition in high-fat diet fed ApoE(-/-) mice

机译:阿魏酸改善非酒精性脂肪肝疾病,并调节高脂饮食喂养ApoE( - / - )小鼠的肠道微生物群组合物

获取原文
获取原文并翻译 | 示例
           

摘要

The objective of this study was to investigate the effects of ferulic acid (FA) on nonalcoholic fatty liver disease (NAFLD) and gut microbiota, and its regulation mechanism in ApoE(-/-) mice fed on a high-fat diet (HFD). Liver morphology, blood lipids, gut microbiota and their metabolite indole-3-acetic acid (I3A) were determined in ApoE(-/-) mice. We also examined the hepatic expression of aryl hydrocarbon receptor (AHR), which inhibits the expression of fatty acid synthase (FASN) and sterol regulatory element-binding protein 1c (SREBP-1c), and ultimately reduces the deposition of triglycerides (TG) and total cholesterol (TC) in the liver. The results of the animal experiment showed that oral administration of FA markedly alleviated the formation of NAFLD and decreased the levels of serum TC, TG and low-density lipoprotein cholesterol (LDL-C). Furthermore, FA supplementation altered the composition of gut microbiota, in particular, modulating the ratio of Firmicutes to Bacteroidetes, and decreased the generation of I3A. Additionally, FA could increase the expression of hepatic AHR and inhibit the expression of FASN and SREBP-1c in the liver. Finally, we found that FA did not have hepatorenal toxicity. The findings above illustrate that FA has the potential to ameliorate NAFLD, some of which are closely related to the modulation of specific gut microbiota and the regulation of genes involved in TG and TC metabolism.
机译:本研究的目的是探讨阿魏酸(FA)对非酒精性脂肪肝疾病(NAFLD)和肠道微生物的影响,及其在高脂饮食(HFD)上喂养的Apoe(/ - / - )小鼠的调节机制。在ApoE( - / - )小鼠中测定肝脏形态,血脂,肠道微生物和它们的代谢物吲哚-3-乙酸(I3a)。我们还研究了芳基烃受体(AHR)的肝脏表达,其抑制脂肪酸合酶(FASN)和甾醇调节元素结合蛋白1C(SREBP-1C)的表达,并最终减少了甘油三酯(TG)和肝脏中总胆固醇(TC)。动物实验的结果表明,口服给予FA显着缓解了NAFLD的形成,并降低了血清TC,TG和低密度脂蛋白胆固醇(LDL-C)的水平。此外,FA补充改变了肠道微生物的组成,特别是调节对抗血栓的比例,并降低I3a的产生。此外,FA可以增加肝脏AHR的表达并抑制肝脏中FASN和SREBP-1C的表达。最后,我们发现FA没有肝肾毒性。上述研究结果表明,Fa具有修复NAFLD的可能性,其中一些与特定肠道微生物的调节和参与TG和TC代谢的基因的调节密切相关。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号